Al- Anbar Medical Journal

Effect of Antibiotic on Men with Raised Prostatic-Specific Antigen (4-10 ng/ml)

Document Type : Original articles

Authors

1 Department of Surgery (Urology), Al-Ramadi Teaching Hospital, Anbar Health Directorate, Ramadi, Anbar, Ira

2 Department of Surgery (General Surgery), Al-Ramadi Teaching Hospital, Anbar Health Directorate, Ramadi, Anbar, Iraq.

Abstract

Background: The managing of raised Prostate-Specific Antigen (PSA) in a range of 4 to 10 ng/ml is still controversial among urologists. In addition to prostatic cancer, benign prostatic hyperplasia, and prostatitis is established to increase PSA. PSA reduction after antibiotic therapy might detect those patients in whom biopsy can be avoided or postponed.
Objectives: To evaluate the effectiveness of a 6 weeks levofloxacin course on the serum total PSA level and PSA density (PSAD) in patients with PSA 4 -10 ng/ml and ordinary digital rectal examination and ultrasonography results.
Materials and Methods: The study conducted at Al-Ramadi Teaching Hospital from February 2016 to December 2019. A total of  177 men with benign prostatic hyperplasia or lower urinary tract symptoms were with a normal digital rectal examination, chronic prostatitis (Expressed prostatic secretion was done before treatment), total PSA 4-10 ng/ml, and ultrasonography findings that did not reveal a hypoechoic lesion in the prostate will be included in this study. Serum PSA and PSAD were measured before, and after treatment with a 6 weeks course of levofloxacin.
Results: The age of our 177 men was ranged from 40-80 years with a mean age of 56.52 years ± 7.253. The mean prostatic size was 49.5 ± 28.5 g (range, 23-150 g). In 89 (50.2%) patients of the 177 men, total PSA has normalized to less than 4 ng/ml after antibiotics treatment. In 56 patients of 89 men had a high level of PSAD. PSAD was normalized (less than 0.15 ng/ml/cm3) after treatment in 49 patients of the 56 patients. A significant reduction in total PSA and PSAD after treatment (p <0.05). 

Keywords

Main Subjects

References
[1]      M. V Sadi, “PSA screening for prostate cancer,” Rev. Assoc. Med. Bras., vol. 63, no. 8, pp. 722–725, 2017.
[2]      H. Erol, N. Beder, T. Çalişkan, M. Dündar, A. İnsal, and N. Çulhaci, “Can the effect of antibiotherapy and anti-inflammatory therapy on serum PSA levels discriminate between benign and malign prostatic pathologies?,” Urol. Int., vol. 76, no. 1, pp. 20–26, 2006.
[3]      K. T. Buddingh, M. G. F. Maatje, H. Putter, R. F. Kropman, and R. C. M. Pelger, “Do antibiotics decrease prostate-specific antigen levels and reduce the need for prostate biopsy in type IV prostatitis? A systematic literature review,” Can. Urol. Assoc. J., 2018.
[4]      A. Saribacak et al., “The role of empiric antibiotic treatment in preventing unnecessary prostate biopsies in asymptomatic patients with PSA levels between 4 and 10 ng/ml,” Int. J. Clin. Exp. Med., vol. 7, no. 8, p. 2230, 2014.
[5]      H. A. Atalay, L. Canat, İ. Alkan, S. S. Çakir, and F. Altunrende, “Prostate-specific antigen reduction after empiric antibiotic treatment does not rule out biopsy in patients with lower urinary tract symptoms: prospective, controlled, single-center study,” Prostate Int., 2017.
[6]      A. R. Zlotta et al., “The effect of lifestyle changes on serum PSA levels in a cohort of asymptomatic men with PSA between 2-10 ng/ml and normal DRE,” Eur. Urol. Suppl., vol. 18, no. 1, p. e1814, 2019.
[7]      S. Carlsson et al., “Screening for Prostate Cancer Starting at Age 50–54 Years. A Population-based Cohort Study,” Eur. Urol., 2017.
[8]      A. Ugrinska, E. Bombardieri, M. P. M. Stokkel, F. Crippa, and E. K. J. Pauwels, “Circulating tumor markers and nuclear medicine imaging modlities: Breast, prostate and ovarian cancer,” Q. J. Nucl. Med. Mol. Imaging, vol. 46, no. 2, p. 88, 2002.
[9]      W. F. S. Busato, G. L. Almeida, J. Geraldo, and F. S. Busato, “Does PSA reduction after antibiotic therapy permits postpone prostate biopsy in asymptomatic men with PSA levels between 4 and 10ng/mL?,” Int. braz j urol, vol. 41, no. 2, pp. 329–336, 2015.
[10]    V. Serretta et al., “PSA reduction (after antibiotics) permits to avoid or postpone prostate biopsy in selected patients,” Prostate Cancer Prostatic Dis., vol. 11, no. 2, pp. 148–152, 2008.
[11]    S. A. Kaplan, “Re: Antibacterial Therapy Improves the Effectiveness of Prostate Cancer Detection Using Prostate-Specific Antigen in Patients With Asymptomatic Prostatitis,” J. Urol., 2011.
[12]    G. Karazanashvili and L. Managadze, “Prostate–Specific Antigen (PSA) Value Change after Antibacterial Therapy of Prostate Inflammation, as a Diagnostic Method for Prostate Cancer Screening in Cases of PSA Value within 4–10 ng/ml and Nonsuspicious Results of Digital Rectal Examination,” Eur. Urol., vol. 39, no. 5, pp. 538–543, 2001.
[13]    O. G. Doluoglu, C. Ceylan, F. Kilinc, E. Gazel, B. Resorlu, and O. Odabas, “Is there any association between National Institute of Health category IV prostatitis and prostate-specific antigen levels in patients with low-risk localized prostate cancer?,” Int. braz j urol, vol. 42, no. 2, pp. 346–350, 2016.
[14]    C. B. Bozeman, B. S. Carver, J. A. Eastham, and D. D. Venable, “Treatment of chronic prostatitis lowers serum prostate specific antigen,” J. Urol., vol. 167, no. 4, pp. 1723–1726, 2002.
[15]    D. E. Taha, O. M. Aboumarzouk, I. O. Koraiem, and A. A. Shokeir, “Antibiotic therapy in patients with high prostate-specific antigen: Is it worth considering? A systematic review,” Arab Journal of Urology. 2020.
[16]    W. J. Catalona et al., “Comparison of Digital Rectal Examination and Serum Prostate Specific Antigen in the Early Detection of Prostate Cancer: Results of a Multicenter Clinical Trial of 6,630 Men,” J. Urol., 2017.
[17]    M. S. Litwin and H. J. Tan, “The diagnosis and treatment of prostate cancer: A review,” JAMA - Journal of the American Medical Association. 2017.
[18]    Y.-S. Kyung, H.-C. Lee, and H.-J. Kim, “Changes in serum prostate-specific antigen after treatment with antibiotics in patients with lower urinary tract symptoms/benign prostatic hyperplasia with prostatitis,” Int. Neurourol. J., vol. 14, no. 2, p. 100, 2010.
 
Al- Anbar Medical Journal
Volume 16, Issue 2
December 2020
Page 31-34
Files
Share
Export Citation
Statistics